Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest The City of London Migraine Clinic Stories

2008-09-08 12:00:41

NeurAxon, a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase, has announced encouraging data from its Phase II clinical trial of NXN-188 in patients with migraine. In the study, patients experiencing migraine with aura achieved sustained relief from their headaches, representing a potentially differentiated treatment profile from current migraine therapies. Data from the Phase II trial showed that patients receiving NXN-188 experienced a 15% greater...

2008-09-08 12:00:08

CoLucid Pharmaceuticals has announced positive Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. The randomized, double-blind study evaluated 130 migraine patients. Patients were not on prophylaxis and received 2.5 to 45mg of COL-144 or placebo as an intravenous infusion over 20 minutes as first-line treatment of an acute migraine attack. The primary end-point...

2008-09-06 03:00:05

LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches. COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), which unlike triptans, exhibits anti-migraine activity without causing...

2008-09-05 09:00:38

NeurAxon, Inc., a developer of next-generation pain therapeutics targeting neuronal nitric oxide synthase (nNOS), today announced data from its Phase 2 clinical trial of NXN-188 in patients with migraine. In the study, patients experiencing migraine with aura, which represents over 7 million patients in the US, achieved sustained relief from their headaches, representing a potentially differentiated treatment profile from current migraine therapies. These data were presented in a session at...

2008-07-16 09:00:15

MOUNTAIN VIEW, Calif., July 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced that the positive results from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics were published in the July issue of Current Medical Research and Opinion. MAP Pharmaceuticals is developing MAP0004, an orally inhaled and self-administered therapy, as a potential treatment for migraine. The study results, which were first announced last year,...

2008-07-15 12:01:01

Map Pharmaceuticals has initiated its Phase III clinical program to evaluate MAP0004 as a potential treatment for migraine. This randomized, double-blind, placebo-controlled Phase III trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. Map will also evaluate earliest onset of pain relief and sustained...

2008-06-30 12:02:03

NuPathe Inc., a privately held specialty pharmaceutical company developing innovative products for the treatment of neurological and psychiatric diseases, announced positive Phase I results for NP101, a novel drug-device patch for acute migraine in clinical development. NP101 combines NuPathe's SmartRelief(TM) proprietary iontophoretic transdermal technology with sumatriptan, the most widely prescribed treatment for acute migraine in the United States and the active ingredient in...

2008-06-30 09:02:17

LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to meeting the primary endpoint of headache pain relief at two hours, the company's lead AMPA/kainate-type glutamate receptor antagonist, tezampanel, demonstrated improvement on important secondary endpoints in a 306-patient Phase IIb clinical trial in acute migraine headache....

2008-06-27 12:02:19

Merck & Co., Inc. today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and migraine-associated symptoms two hours after dosing compared to placebo. In addition, the efficacy results for telcagepant 300 mg were similar to the highest recommended dose of zolmitriptan,(1) an approved migraine therapy, with a lower incidence of...

e11e4409afee073fcc6017ca61d0e9751
2008-06-26 09:00:00

Neuralieve, a medical technology company pioneering a new approach to treat migraine headache, today reported completion of its clinical trial. The results will be presented June 27 during the annual American Headache Society (AHS) scientific meeting in Boston by Dr. Richard B. Lipton, Professor and Vice Chair of Neurology and Professor of Epidemiology and Population Health at the Albert Einstein College of Medicine in New York. The randomized, double-blind, parallel-group, sham-controlled...